FDA Recalls Fexofenadine Allergy Relief Tablets Due to Impurity and Degradation Issues
Target's store-brand fexofenadine allergy relief tablets are being recalled nationwide due to failed quality specifications for impurities and degradation. Consumers should stop using affected lots and contact Target or their healthcare provider.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Class II FDA drug recall with no reported illnesses or injuries. The hazard—failed quality specifications for impurities and degradation—is concerning but theoretical, without specific impurities or documented health risks identified in the source.
Plain-English summary
L. Perrigo Company is recalling fexofenadine hydrochloride 180 mg tablets, an over-the-counter allergy relief medication sold at Target Corporation stores nationwide. The recall affects 208,416 cartons in 15, 30, 70, and 150-count packages with multiple lot numbers and expiration dates between December 2023 and February 2024.
The tablets are being recalled because they failed to meet specifications for impurities and degradation. The source does not specify which impurities were detected or describe any identified health risks associated with the failed specifications.
No illnesses or injuries have been reported related to this recall. Consumers with affected lot numbers should stop using the product and consult Target or their healthcare provider. Lot numbers and expiration dates are available in the FDA's official recall notice.
The recalled product
- Product
- allergy relief, Fexofenadine Hydrochloride Tablets, 180 mg, packaged in a)15-count cartons (NDC 11673-617-22), b)30-count cartons (NDC 11673-617-39), c)70-count cartons (NDC 11673-617-01), and d)150-count cartons (11673-617-47), Distributed by: Target Corporation, Minneapolis, MN
- Manufacturer
- L. Perrigo Company
- Hazard
- impurity
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lot #: a) 2HE2032
- 2JE1882
- 2JE2185 Exp. Date 01/24
- b) 2DR0464
- 2ER0410
- Exp. Date 12/23
- 2ER0286
- 2ER0411
- Exp. Date 01/24 c) 2DR0467
- 2DR0468
- 2DR0469
- 2ER0288
- Exp. Date 12/23 d) 2ER0414
- Exp. Date 01/24
- 2GR0333
- Exp. Date 02/24
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27